This site is intended for health professionals only
During Pulse PCN Events, you will also have the opportunity to find out more about the latest innovations from our handpick selection of suppliers. By clicking on the logo you will be able to access their websites and learn more about the latest products and services.
If you are interested in participating, please contact us.Interested in exhibiting?
Our mission at Glenmark Respiratory UK is to be a consistent presence in the UK respiratory market, with an unwavering focus on patients. We believe in working with healthcare providers to help overcome barriers they face. We value simplicity and efficiency, values that are upheld by our respiratory brands.
Adverse event reporting information available in documents below.
PP-UK-RYAL-0104 May 2022
Anima is the next generation online consultation platform for PCNs and GP practice teams. Anima provides PCNs and practice teams with everything you need to manage any patient request end-to-end in a single platform. Unprecedented levels of control, customisation and automation and productivity tools help supercharge your entire team and co-ordinate great care across your organisation. Built by doctors, approved by NHS Digital, and integrated with EMIS & SystmOne, Anima really is the “most advanced GP consultation platform around” (eGPlearning).
We provide remote triage, additional capacity appointments and first contact consultation service for electronic requests. Our aim is to complete as many contacts as possible to reduce the workload on practices. However, we’re not a tech company, we provide clinicians offering personal patient contact. Our service can be expanded to support other ‘on the day’ demand for practices.
Our core team consists of experienced Physician Associates and supervised by our GP’s. This team can be supplemented with physiotherapists, nurses, paramedics, mental health workers and other clinicians to ensure local demand is managed appropriately.
Email [email protected]
Tel: 0330 1185048
Galderma is a leader in research and development of scientifically defined and medically proven dermatology solutions seeking to enhance the quality of patient’s lives. Galderma’s Prescription Medicine business is focused on prescription treatments that offer patients relief from the burden of mild, moderate and severe skin diseases and is supported by a wide-ranging portfolio with innovation focused on the development of new therapies in disease areas with current unmet medical needs.
Pioneer in its field, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the first non-invasive solution to assess and monitor patients with chronic liver disease. FibroScan® is recognized worldwide as the reference for non-invasive liver fibrosis and liver steatosis assessment with more than 3,000+ peer reviewed publications and 140+ international guidelines recommendations. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide.
No more long paper lists of patients for QOF review.
Codepilot reduces GP workload by identifying patients that are missing from disease registers.
Distribute these records electronically to the most appropriate staff member for review. Codepilot halves the time it normally takes to do each of these reviews.
Correctly coding patients results in improved quality of care for patients and increased income for the practice.
See how Codepilot can help your practice by visiting our stand or www.codepilot.app
Prescribing Care Direct (PCD) has recognised an increasing need for the deployment of practice pharmacist services. We provide a range of primary care medicines optimisation services, including care home and discharge support.
At PCD, we have highlighted that general practitioners spend approximately 20 – 30% of their time dealing with an extensive range of activities relating to prescribing.
The aims of the services provided by PCD are to reduce the workload of the GP through our highly skilled and experienced workforce.
As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. In the UK, we employ approximately 1,300 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in R&D and is the single largest industry sponsor of clinical trials in the UK. For more information, please visit www.novartis.co.uk
Chiesi Limited is headquartered in Manchester and employs over 400 people. Based in Parma, Italy, Chiesi Farmaceutici is an international research-oriented group with over 80 years’ experience in the pharmaceutical sector, operating in 29 countries and employing around 5,700 people.
Chiesi researches, develops and markets innovative drugs for respiratory treatment, special care medicine, and rare diseases, with its Research and Development Centre also based in Parma. Chiesi is a certified Benefit Corporation (B Corp®) and is committed to operating in an environmentally responsible manner.
Pulse Intelligence allows you to match your practice to others around the country and highlight ways in which you can maximise your own practice profits. Using official NHS data, we have collected information on your income, staff, and practice demographics to provide a whole picture on your practice’s finances, and offers guidance articles on how you can improve your funding.